Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jonathan Ellichman

Vascular Surgery Memphis, TN Medical Doctor

NPI 1073538823 CMS profile 48053

6401 Poplar Ave Ste 410, Memphis, TN 38119

Open in the dashboard

General payments

$3,786

58 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jonathan Ellichman of Memphis, TN is reported in the CMS Open Payments database as having received $3,786 across 58 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 43rd percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $675 7
2024 General $444 7
2023 General $235 7
2022 General $92 5
2021 General $616 9
2020 General $1,530 15
2019 General $192 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jonathan Ellichman
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Jonathan Ellichman were reported at $675. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Jonathan Ellichman Vascular Surgery median Middle half National median
2019 $192 $796 $226–$2,363 $163
2020 $1,530 $348 $118–$1,110 $114
2021 $616 $471 $158–$1,421 $132
2022 $92 $725 $222–$2,183 $149
2023 $235 $836 $257–$2,440 $160
2024 $444 $909 $252–$2,619 $164
2025 $675 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bard Peripheral Vascular, Inc. $1,814 19 payments
  2. Cardiovascular Systems Inc. $430 17 payments
  3. AngioDynamics, Inc. $401 2 payments
  4. Medtronic, Inc. $300 2 payments
  5. Penumbra, Inc. $244 2 payments
  6. Philips Electronics North America Corporation $146 2 payments
  7. Becton, Dickinson and Company $146 3 payments
  8. TissueTech, Inc. $136 4 payments
  9. Abbott Laboratories $62 2 payments
  10. Cardinal Health 200, LLC $29 1 payment
  11. Other $76 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,113 51 payments
  2. Travel and Lodging $945 5 payments
  3. Education $377 1 payment
  4. Consulting Fee $350 1 payment
Products named General payments · program years 2019–2025
  1. CROSSER $945 5 payments
  2. Peripheral Orbital Atherectomy System $313 12 payments
  3. ENDURANT IIS $300 2 payments
  4. RotarexS 6 F x 135 cm $220 3 payments
  5. LUTONIX $187 1 payment
  6. Indigo System $150 1 payment
  7. IV Other $117 1 payment
  8. NEOX $104 3 payments
  9. CLARIX $104 3 payments
  10. Penumbra System $95 1 payment
  11. Other $413 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

41

Median for Cardiac Surgery: 68

Drug cost

$418

Median for Cardiac Surgery: $445

Branded share of claims

100%

Median for Cardiac Surgery: 15.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 41 $418

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 411 Part D prescribers listed as Cardiac Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$629,898

Of which drugs: $395

Medicare patients

154

Average age 75

Services billed

1,148

80 women, 74 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 49%
Arthritis 49%
Ischemic heart disease 39%
Chronic kidney disease 34%
Heart failure 21%
Atrial fibrillation 19%
COPD 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, protamine sulfate, per 10 mg J2720 Office 36 188 $233
Infusion, normal saline solution, sterile (500 ml = 1 unit) J7040 Office 34 60 $62
Injection, cefazolin sodium, 500 mg J0690 Office 14 46 $29
Injection, diphenhydramine hcl, up to 50 mg J1200 Office 24 35 $22
Injection, midazolam hydrochloride, per 1 mg J2250 Office 23 76 $8

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

58 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record